biota beyond the idiotic management, page-3

lol abobo

there was an article recently quoting the head of GSK saying they will modify Relenza so it does not need to be taken through an inhaler and this will ramp up the output to 160 million annually.

I figure that to be around $300 million in annual royalties so it does massively undervalue Biota.

Dont worry the shares will go up. I think it is a certainty with the royalties that will come their way and with the emphasise now so much on Influenza and with the resistance to Tamiflu etc.

It is like knowing the winner of a race in advance imo